✦ LIBER ✦

PMS39 Cost-Effectiveness Analysis of Certolizumab Pegol in Patients With Rheumathoid Arthritis from a Brazilian Private Perspective

✍ Scribed by T. Piha; E.D.S. Meirelles; W. Kuriki; P.A. Miranda

Book ID: 119312240
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 61 KB
Volume: 15
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.08.1394

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Modelling of a 3-Mont

Cost-Effectiveness Modelling of a 3-Month Tight Control Patient Management of Rheumatoid Arthritis with Certolizumab Pegol in France

✍ Fagnani, F.; Pham, T.; Claudepierre, P.; Berenbaum, F.; De Chalus, T.; Saadoun, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PMS33 Cost-Effectiveness and Budget Impa

PMS33 Cost-Effectiveness and Budget Impact Analysis of Viscosupplementation with Orthovisc™ (Hyaluronan) in Knee Osteoarthritis, from the Brazilian Private Health Care System Perspective

✍ M.U. Rezende; A.J. Hernandez; M.M. Namba; R.A. Fernandes; M.L.S. Takemoto; P.M.L 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Comparing Costs Per Clinical Remission o

Comparing Costs Per Clinical Remission of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: A Brazilian Private Perspective

✍ Buschinelli, C.T.; Tsuchiya, C.T.; Maximo, M.F.M.; Tobaruella, F.S.; Gonçalves, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

American College of Rheumatology hybrid

American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: Data from a 52-week phase III trial

✍ R. F. van Vollenhoven; D. Felson; V. Strand; M. E. Weinblatt; K. Luijtens; E. C. 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 101 KB 👁 2 views

## Abstract ## Objective The American College of Rheumatology (ACR) hybrid (a modified mean percent response to treatment) was officially recommended by the ACR as a revision to 20%, 50%, and 70% response criteria (ACR20/50/70) scores, but has not been tested in clinical trials. We performed a pos

PMS10 THE COST-EFFECTIVENESS OF ABATACEP

PMS10 THE COST-EFFECTIVENESS OF ABATACEPT VERSUS RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PERSPECTIVE OF THE CANADIAN PUBLICLY FUNDED HEALTH CARE SYSTEM

✍ Y Yuan; M Maier-Moldovan; R Maclean; GJ L'Italien 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PMS27 A COST-EFFECTIVENESS ANALYSIS FROM

PMS27 A COST-EFFECTIVENESS ANALYSIS FROM AN INSTITUTIONAL PERSPECTIVE TO COMPARE ZOLEDRONIC ACID WITH STANDARD OF CARE IN THE PREVENTION OF HIP FRACTURES IN PATIENTS WITH OSTEOPOROSIS

✍ B. Briones; M.G. Bravo; F. García-Contreras 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB